CD4 and neoplasm: More recent advances have been associated with individualized vaccines using tumor whole exome sequencing to identify autologous neoantigens, which have been shown to be immunogenic for intratumoral CD4+ and CD8+ T cell responses in early phase clinical trials in glioblastoma (180).